Helicobacter pylori eradication prevents recurrence after simple closure of perforated duodenal ulcer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 3, 2007, Pages 345-348

  Bose, Ashitha C ^a   Kate, Vikram ^a   Ananthakrishnan, Nilakantan ^a   Parija, Subhash Chandra ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Complicated duodenal ulcer; Eradication therapy; H. pylori; Recurrent duodenal ulcer

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; OMEPRAZOLE; PROBIOTIC AGENT; UREASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DUODENUM ULCER; ERADICATION THERAPY; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME; ULCER PERFORATION;

EID: 33846927056     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04490.x     Document Type: Article

References (25)

1. Chowdhary SK, Bhasin DK, Panigrahi D et al. Helicobacter pylori infection in patients with perforated duodenal ulcer. Trop. Gastroenterol. 1998; 19: 19-21.
2. 2-receptor antagonists. Ann. Surg. 1988; 207: 4-6.
3. Griffin GE, Organ CH Jr. The natural history of perforated duodenal ulcer treated by suture plication. Ann. Surg. 1976; 183: 382-5.
4. Jordan PHJ, Thornby J. Perforated pyloroduodenal ulcers: long-term results with omental patch closure and parietal cell vagotomy. Ann. Surg. 1995; 221: 479-86.
5. 2-antagonists. Ann. R. Coll. Surg. Engl. 1986; 68: 240-2.
6. Sevvel S, Ananthakrishnan N, Kate V. Role of Histamine-2 receptor antagonists after simple closure of perforated duodenal ulcer - a double blind randomized controlled study. Trop. Gastroenterol. 1996; 17: 227-9.
7. Macintyre IM, Miller A. Impact of H-2 receptor antagonists on the outcome of treatment of perforated duodenal ulcer. J. R. Coll. Surg. Edinb. 1990; 35: 348-52.
8. Jensen DM, You S, Pelayo E, Jensen ME. The prevalence of H. pylori and NSAID use in patients with severe upper gastrointestinal hemorrhage and their potential role in recurrence of ulcer bleeding. Gastroenterology 1992; 102: A90.
9. Sebastian M, Prem Chandran VP, Elashaal YIM, Sim AJ. Helicobacter pylori infection in perforated peptic ulcer disease. Br. J. Surg. 1995; 82: 360-2.
10. Reinbach DH, Cruickshank G, McColl KEL. Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection. Gut 1993; 34: 1344-7.
11. Ng EK, Lam YH, Sung JJ et al. Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. Ann. Surg. 2000; 231: 153-8.
12. Kate V, Ananthakrishnan N, Badrinath S. Effect of Helicobacter pylori eradication on the ulcer recurrence rate after simple closure of perforated duodenal ulcer: retrospective and prospective randomized controlled studies. Br. J. Surg. 2001; 88: 1054-8.
13. Kate V, Ananthakrishnan N. Treatment of Helicobacter pylori infection: a review. Indian J. Pharmacol. 2001; 33: 410-6.
14. Marshall BJ, Warren JR, Francis GJ, Langton SR, Goodwin CS, Blincow EJ. Rapid urease test in the management of Campylobacter pyloridis associated gastritis. Am. J. Gastroenterol. 1987; 82: 200-10.
15. Blakstone MO. Endoscopic Interpretation. New York: Raven Press, 1984.
16. Whitehead R. Mucosal Biopsy of the Gastrointestinal Tract, 3rd edn. Philadelphia: Saunders, 1985.
17. Jones VS, Kate V, Ananthakrishnan N, Badrinath S, Amarnath SK, Ratnakar C. Standardization of urease test for detection of Helicobacter pylori. Indian J. Med. Microbiol. 1997; 15: 181-3.
18. Armuzzi A, Cremonini F, Ojetti V. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion 2001; 63: 1-7.
19. Canducci F, Armuzzi A, Cremonini F. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment. Pharmacol. Ther. 2000; 14: 1625-9.
20. Huang HQ, Chiba N, Wilkinson JM, Hunt RH. Attempt by meta-analysis to define the optimal treatment regimen for eradicating Helicobacter pylori (H. pylori) infection. Can. J. Gastroenterol. 1997; 11: 44A.
21. Kumar D, Sinha AN. Helicobacter pylori infection delays ulcer healing in patients operated on for perforated duodenal ulcer. Indian J. Gastroenterol. 2002; 21: 19-22.
22. Matsukura N, Onda M, Tokunaga A et al. Role of Helicobacter pylori infection in perforation of peptic ulcer: an age- and gender-matched case-control study. J. Clin. Gastroenterol. 1997; 25 (Suppl. 1): S235-9.
23. Wong WM, Gu Q, Lam SK et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy versus quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2003; 17: 553-60.
24. Miehlke S, Kirsch C, Schneider-Brachert W et al. A prospective randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003; 8: 310-19.
25. Calvet X, Ducons J, Guardiola J et al. One week triple versus quadruple therapy for Helicobacter pylori infection - a randomized trial. Group for eradication studies from Catalonia and Aragon (Gresca). Aliment. Pharmacol. Ther. 2002; 16: 1261-7.